司库奇尤单抗与乌司奴单抗治疗银屑病对生活质量、工作生产力和活动损害的不同影响:结构方程模型分析
基于CLEAR研究数据,采用结构方程模型分析司库奇尤单抗与乌司奴单抗对银屑病患者生活质量(DLQI)和工作生产力及活动损害(WPAI)的直接与间接效应,以PASI严重程度及症状(疼痛、瘙痒、脱屑)为潜在中介。第16周和第52周结果显示,治疗对DLQI变化的影响由PASI 90应答及瘙痒、疼痛、脱屑改善所中介;早期(第16周)达到任何PASI应答直接带来显著更优的WPAI评分;所有结果均支持司库奇尤单抗优于乌司奴单抗。
要点
- 第16周和第52周,治疗对DLQI变化的影响由PASI 90应答及瘙痒、疼痛、脱屑改善所中介。
- 第16周达到任何PASI应答直接带来显著更优的WPAI评分;第52周PASI应答和脱屑改善直接带来显著更优WPAI评分。
- 疼痛、瘙痒和脱屑相互相关(r=0.51-0.68),任一改善对WPAI有显著直接或间接影响;所有结果均支持司库奇尤单抗优于乌司奴单抗。
核心结论
- 结果强调PASI应答和症状减轻对改善健康相关生活质量及工作与日常活动的重要作用,且所有结果均支持司库奇尤单抗优于乌司奴单抗。
研究设计与样本
- 基于CLEAR研究数据的结构方程模型分析,主要分析第16周达到PASI 90应答(PASI较基线改善≥90%)的患者,并在第52周重复,同时分析PASI 50、75和100应答。
主要发现
- 第16周和第52周,治疗对DLQI评分变化的影响由PASI 90应答及瘙痒、疼痛、脱屑改善所中介。
- 第16周达到任何PASI应答直接导致显著更优的WPAI评分;第52周PASI应答和脱屑改善直接导致显著更优的WPAI评分。
- 疼痛、瘙痒和脱屑相互相关(r=0.51-0.68),任一改善对WPAI有显著直接或间接影响;所有结果均支持司库奇尤单抗优于乌司奴单抗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients, such as sleep impairment, depressive symptoms, negative self-esteem and reduced work productivity. OBJECTIVES: To examine direct and indirect (mediated) effects of secukinumab vs. ustekinumab on quality of life, work productivity and activity impairment based on psoriasis severity and symptoms. METHODS: Analyses were based on data from the CLEAR study. Structural equation modelling examined the effects of secukinumab vs. ustekinumab on the Dermatology Life Quality Index (DLQI) and on the Work Productivity and Activity Impairment (WPAI) questionnaire using Psoriasis Area and Severity Index (PASI) severity and symptoms (pain, itching and scaling) as potential mediators. Analyses were conducted primarily for patients achieving a PASI 90 response (90% or greater reduction in PASI from baseline) at week 16 (repeated at week 52) and for PASI 50, 75 and 100. RESULTS: Results at weeks 16 and 52 showed that the effect of treatment on change in DLQI score was mediated by the PASI 90 response and by improvements in itching, pain, and scaling. Achieving any PASI response as early as week 16 directly resulted in significantly better WPAI scores. At week 52, both PASI response and improvement in scaling directly resulted in significantly better WPAI scores. Pain, itching and scaling were correlated (r = 0·51-0·68); improvement in any of these had a significant effect (directly or indirectly) on WPAI. All results favoured secukinumab over ustekinumab. CONCLUSIONS: The results underscore the important role of both PASI response and reduction in symptoms on improvements in health-related quality of life and work and daily activity in favour of secukinumab vs. ustekinumab.
引用
- Stull DE, Griffiths CEM, Gilloteau I, et al. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018. PMID: 29355896. doi:10.1111/bjd.16366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。